Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

Fig. 2

Biomarker panel for prediction of prostate cancer aggressiveness. Box plot representing significant changes of biomarker levels in different biofluids: a Serum total PSA, b sTWEAK semen levels, c mRNA levels in semen cell sediment of: Fn14, KLK2, CXCR2 and CCR3, and d fasting glucose levels. Values of each biomarker are expressed as mean ± SD. Differences between patients according to Gleason stage coded into two categories: low-risk ISUP GG (group I and II) or high-risk ISUP GG (group III, IV and V) were tested with the Mann–Whitney U test for non-normally distributed data. p-values less than 0.05 were considered statistically significant

Back to article page